White paper on microbial anti-cancer therapy and prevention

[1]  M. Coffey,et al.  Oncolytic reovirus therapy: Pilot study in dogs with spontaneously occurring tumours , 2018, Veterinary and comparative oncology.

[2]  T. Dipetrillo,et al.  Tolerability of ADXS11-001 Lm-LLO Listeria-Based Immunotherapy With Mitomycin, Fluorouracil, and Radiation for Anal Cancer. , 2018, International journal of radiation oncology, biology, physics.

[3]  M. Agbandje-McKenna,et al.  Optimizing the Targeting of Mouse Parvovirus 1 to Murine Melanoma Selects for Recombinant Genomes and Novel Mutations in the Viral Capsid Gene , 2018, Viruses.

[4]  E. Jaffee,et al.  Tumor Mutational Burden and Response Rate to PD-1 Inhibition. , 2017, The New England journal of medicine.

[5]  A. Unterberg,et al.  Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity , 2017, Viruses.

[6]  S. Lam,et al.  Harnessing innate lung anti-cancer effector functions with a novel bacterial-derived immunotherapy , 2017, Oncoimmunology.

[7]  Marijo Bilusic,et al.  Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations , 2017, Human vaccines & immunotherapeutics.

[8]  Andrew L Laccetti,et al.  Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg? , 2017, Current opinion in urology.

[9]  S. Gottschalk,et al.  Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  Hellmut G. Augustin,et al.  Preclinical mouse solid tumour models: status quo, challenges and perspectives , 2017, Nature Reviews Cancer.

[11]  Nir Hacohen,et al.  Resistance to checkpoint blockade therapy through inactivation of antigen presentation , 2017, Nature Communications.

[12]  A. Hauschild,et al.  Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Vance,et al.  Evolutionary Origins of cGAS-STING Signaling. , 2017, Trends in immunology.

[14]  Michael E. Lassman,et al.  Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy , 2017, Cell.

[15]  N. Halama,et al.  A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol , 2017, BMC Cancer.

[16]  A. Unterberg,et al.  Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  E. Jaffee,et al.  Targeting neoantigens to augment antitumour immunity , 2017, Nature Reviews Cancer.

[18]  J. Suzich,et al.  Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  B. Monk,et al.  Therapeutic options for treatment of human papillomavirus-associated cancers - novel immunologic vaccines: ADXS11–001 , 2017, Gynecologic Oncology Research and Practice.

[20]  R. Ponce,et al.  Local Delivery of OncoVEXmGM-CSF Generates Systemic Antitumor Immune Responses Enhanced by Cytotoxic T-Lymphocyte–Associated Protein Blockade , 2017, Clinical Cancer Research.

[21]  M. Redinbo,et al.  The role of the microbiome in cancer development and therapy , 2017, CA: a cancer journal for clinicians.

[22]  B. C. Selvanesan,et al.  Immunotherapy with Listeria reduces metastatic breast cancer in young and old mice through different mechanisms , 2017, Oncoimmunology.

[23]  E. Chiocca,et al.  Oncolytic Viruses in Cancer Treatment: A Review , 2017, JAMA oncology.

[24]  R. Kelly,et al.  The Evolving Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancer. , 2017, Hematology/oncology clinics of North America.

[25]  D. Mahalingam,et al.  Review: Oncolytic Virotherapy, updates and future directions. , 2017, Oncotarget.

[26]  W. Debinski,et al.  Novel molecular multilevel targeted antitumor agents , 2017, Cancer translational medicine.

[27]  Zin W. Myint,et al.  Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress , 2017, Journal of Hematology & Oncology.

[28]  S. Gottschalk,et al.  Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors. , 2017, Cancer research.

[29]  S. Weiss,et al.  Therapeutic benefit of Salmonella attributed to LPS and TNF-α is exhaustible and dictated by tumor susceptibility , 2017, Oncotarget.

[30]  P. Agarwal,et al.  Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy , 2017, Oncoimmunology.

[31]  I. Wistuba,et al.  VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer , 2017, Nature Medicine.

[32]  A. Wege,et al.  Humanized Mice with Subcutaneous Human Solid Tumors for Immune Response Analysis of Vaccinia Virus-Mediated Oncolysis , 2017, Molecular therapy oncolytics.

[33]  S. Russell,et al.  How to develop viruses into anticancer weapons , 2017, PLoS pathogens.

[34]  J. Johnston,et al.  Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors. , 2017, Human gene therapy. Clinical development.

[35]  C. Zahnow,et al.  Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. , 2017, Cancer discovery.

[36]  E. Jaffee,et al.  Targeting neoantigens to augment antitumour immunity , 2017, Nature Reviews Cancer.

[37]  S. Carter,et al.  Loss of PTEN Is Associated with Resistance to Anti‐PD‐1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma , 2017, Immunity.

[38]  C. Drake,et al.  Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment , 2017, Journal of the National Cancer Institute.

[39]  A. Casadevall,et al.  32-Phosphorus selectively delivered by listeria to pancreatic cancer demonstrates a strong therapeutic effect , 2017, Oncotarget.

[40]  T. Graeber,et al.  Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. , 2017, Cancer discovery.

[41]  B. Leuchs,et al.  A novel scalable, robust downstream process for oncolytic rat parvovirus: isoelectric point-based elimination of empty particles , 2017, Applied Microbiology and Biotechnology.

[42]  Jos Jonkers,et al.  Genetically engineered mouse models in oncology research and cancer medicine , 2016, EMBO molecular medicine.

[43]  J. Modiano,et al.  Canine cancer immunotherapy studies: linking mouse and human , 2016, Journal of Immunotherapy for Cancer.

[44]  L. Zitvogel,et al.  Immunogenic cell death in cancer and infectious disease , 2016, Nature Reviews Immunology.

[45]  E. Jaffee,et al.  Current progress in immunotherapy for pancreatic cancer. , 2016, Cancer letters.

[46]  D. Powell,et al.  Feasibility and Safety of RNA-transfected CD20-specific Chimeric Antigen Receptor T Cells in Dogs with Spontaneous B Cell Lymphoma. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[47]  M. Omar Din,et al.  Synchronized cycles of bacterial lysis for in vivo delivery , 2016, Nature.

[48]  T. Graeber,et al.  Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. , 2016, The New England journal of medicine.

[49]  C. Breitbach,et al.  Oncolytic Viruses: Therapeutics With an Identity Crisis , 2016, EBioMedicine.

[50]  M. Vetizou,et al.  Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. , 2016, Immunity.

[51]  J. Modiano,et al.  A phase I clinical study to evaluate safety of orally administered, genetically engineered Salmonella enterica serovar Typhimurium for canine osteosarcoma , 2016, Veterinary medicine and science.

[52]  G. Freeman,et al.  Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. , 2016, Immunity.

[53]  Ahir Gopaldas.  Therapy , 2016, Indian Journal of Nuclear Medicine : IJNM : The Official Journal of the Society of Nuclear Medicine, India.

[54]  E. Rankin,et al.  Hypoxic control of metastasis , 2016, Science.

[55]  M. Coffey,et al.  Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses , 2016, Molecular therapy. Methods & clinical development.

[56]  J. Rojas,et al.  Manipulating TLR Signaling Increases the Anti-tumor T Cell Response Induced by Viral Cancer Therapies , 2016, Cell reports.

[57]  S. Weiss,et al.  Bacteria in Cancer Therapy: Renaissance of an Old Concept , 2016, International journal of microbiology.

[58]  Jedd D. Wolchok,et al.  PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations , 2016, Science Translational Medicine.

[59]  B. Leuchs,et al.  Standardized large-scale H-1PV production process with efficient quality and quantity monitoring. , 2016, Journal of virological methods.

[60]  J. McQuade,et al.  Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. , 2016, Cancer discovery.

[61]  L. Zitvogel,et al.  Trial Watch—Oncolytic viruses and cancer therapy , 2016, Oncoimmunology.

[62]  J. Prieto,et al.  Immunological landscape and immunotherapy of hepatocellular carcinoma , 2015, Nature Reviews Gastroenterology &Hepatology.

[63]  J. Brody,et al.  In situ vaccination: Cancer immunotherapy both personalized and off‐the‐shelf , 2015, Molecular oncology.

[64]  F. Ginhoux,et al.  Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota , 2015, Science.

[65]  Jason B. Williams,et al.  Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy , 2015, Science.

[66]  P. Lizotte,et al.  In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer , 2015, Nature nanotechnology.

[67]  J. Modiano,et al.  Progress in Adaptive Immunotherapy for Cancer in Companion Animals: Success on the Path to a Cure , 2015, Veterinary sciences.

[68]  C. Guzmán,et al.  Induction of CD4+ and CD8+ anti‐tumor effector T cell responses by bacteria mediated tumor therapy , 2015, International journal of cancer.

[69]  R. Hoffman,et al.  Imaging the Different Mechanisms of Prostate Cancer Cell-killing by Tumor-targeting Salmonella typhimurium A1-R. , 2015, Anticancer research.

[70]  M. Manns,et al.  Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[71]  A. Troxel,et al.  Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma. , 2015, Blood.

[72]  H. Kohrt,et al.  In-situ tumor vaccination: Bringing the fight to the tumor , 2015, Human vaccines & immunotherapeutics.

[73]  John D Lambris,et al.  Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[74]  Troy Guthrie,et al.  Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  S. Thorne,et al.  Tunable pH-Responsive Polymeric Micelle for Cancer Treatment. , 2015, ACS macro letters.

[76]  K. Murphy,et al.  Genetic Vaccines To Potentiate the Effective CD103+ Dendritic Cell–Mediated Cross-Priming of Antitumor Immunity , 2015, The Journal of Immunology.

[77]  T. Gajewski,et al.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity , 2015, Nature.

[78]  J. Rommelaere,et al.  Tumor Selectivity of Oncolytic Parvoviruses: From in vitro and Animal Models to Cancer Patients , 2015, Front. Bioeng. Biotechnol..

[79]  E. Jaffee,et al.  Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  C. Drake,et al.  Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.

[81]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[82]  D. Lamm,et al.  Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer , 2015, Nature Reviews Urology.

[83]  K. Kinzler,et al.  Clostridium novyi-NT can cause regression of orthotopically implanted glioblastomas in rats , 2015, Oncotarget.

[84]  N. Forbes,et al.  Quorum-sensing Salmonella selectively trigger protein expression within tumors , 2015, Proceedings of the National Academy of Sciences.

[85]  A. Marchini,et al.  Oncolytic parvoviruses: from basic virology to clinical applications , 2015, Virology Journal.

[86]  F J Gilbert,et al.  Imaging tumour hypoxia with positron emission tomography , 2014, British Journal of Cancer.

[87]  J. Wolchok,et al.  Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer , 2014, Molecular therapy oncolytics.

[88]  M. Coffey,et al.  Phase I Trial of Cyclophosphamide as an Immune Modulator for Optimizing Oncolytic Reovirus Delivery to Solid Tumors , 2014, Clinical Cancer Research.

[89]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[90]  M. Venkataswamy,et al.  Direct incorporation of the NKT-cell activator α-galactosylceramide into a recombinant Listeria monocytogenes improves breast cancer vaccine efficacy , 2014, British Journal of Cancer.

[91]  M. Coffey,et al.  Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[92]  Hao Liu,et al.  Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. , 2014, Cancer research.

[93]  P. Vandenabeele,et al.  Consensus guidelines for the detection of immunogenic cell death , 2014, Oncoimmunology.

[94]  Robert S. Benjamin,et al.  Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses , 2014, Science Translational Medicine.

[95]  N. Forbes,et al.  Lipid A controls the robustness of intratumoral accumulation of attenuated Salmonella in mice , 2014, International journal of cancer.

[96]  Wen-Wei Chang,et al.  Salmonella as an Innovative Therapeutic Antitumor Agent , 2014, International journal of molecular sciences.

[97]  Z. Brentzel,et al.  Bacterial delivery of Staphylococcus aureus α-hemolysin causes regression and necrosis in murine tumors. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[98]  Z. Brentzel,et al.  Identification of Staphylococcus aureus α‐hemolysin as a protein drug that is secreted by anticancer bacteria and rapidly kills cancer cells , 2014, Biotechnology and bioengineering.

[99]  L. Wood,et al.  Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy , 2014, Front. Cell. Infect. Microbiol..

[100]  P. Lizotte,et al.  Attenuated Listeria monocytogenes reprograms M2-polarized tumor-associated macrophages in ovarian cancer leading to iNOS-mediated tumor cell lysis , 2014, Oncoimmunology.

[101]  G. McFadden,et al.  Viruses for tumor therapy. , 2014, Cell host & microbe.

[102]  D. Largaespada,et al.  Mouse models of cancer: Sleeping Beauty transposons for insertional mutagenesis screens and reverse genetic studies. , 2014, Seminars in cell & developmental biology.

[103]  J. Diallo,et al.  From Scourge to Cure: Tumour-Selective Viral Pathogenesis as a New Strategy against Cancer , 2014, PLoS pathogens.

[104]  R. Cattaneo,et al.  New viruses for cancer therapy: meeting clinical needs , 2013, Nature Reviews Microbiology.

[105]  S. Russell,et al.  Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs. , 2013, Human gene therapy. Clinical development.

[106]  D. Chandra,et al.  Myeloid-derived suppressor cells , 2013, Oncoimmunology.

[107]  James J. Choi,et al.  Enhanced Tumor Uptake and Penetration of Virotherapy Using Polymer Stealthing and Focused Ultrasound , 2013, Journal of the National Cancer Institute.

[108]  S. Russell,et al.  Oncolytic vaccines , 2013, Expert review of vaccines.

[109]  E. Kang,et al.  Therapeutic targeting of chitosan-PEG-folate-complexed oncolytic adenovirus for active and systemic cancer gene therapy. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[110]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[111]  J. Wolchok,et al.  At the Bedside: CTLA‐4‐ and PD‐1‐blocking antibodies in cancer immunotherapy , 2013, Journal of leukocyte biology.

[112]  R. Kiessling,et al.  Immunogenic tumor cell death induced by chemoradiotherapy: molecular mechanisms and a clinical translation , 2013, Cell Death and Disease.

[113]  M. Einstein,et al.  Myeloid-derived suppressor cells have a central role in attenuated Listeria monocytogenes-based immunotherapy against metastatic breast cancer in young and old mice , 2013, British Journal of Cancer.

[114]  A. Casadevall,et al.  Nontoxic radioactive Listeriaat is a highly effective therapy against metastatic pancreatic cancer , 2013, Proceedings of the National Academy of Sciences.

[115]  Se Jin Song,et al.  Cohabiting family members share microbiota with one another and with their dogs , 2013, eLife.

[116]  L. Zitvogel,et al.  Trial Watch-Oncolytic viruses and cancer therapy. , 2016 .

[117]  J. Harty,et al.  Pathogen-specific inflammatory milieux tune the antigen sensitivity of CD8(+) T cells by enhancing T cell receptor signaling. , 2013, Immunity.

[118]  Maria G. Castro,et al.  Gene therapy for brain tumors: Basic developments and clinical implementation , 2012, Neuroscience Letters.

[119]  D. Lohse,et al.  Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[120]  E. Chiocca,et al.  Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress. , 2012, Current pharmaceutical biotechnology.

[121]  G. Nuovo,et al.  Cell Carriage, Delivery, and Selective Replication of an Oncolytic Virus in Tumor in Patients , 2012, Science Translational Medicine.

[122]  T. Gajewski,et al.  Cancer immunotherapy , 2012, Molecular oncology.

[123]  D. Louis,et al.  Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells. , 2012, Journal of the National Cancer Institute.

[124]  E. Jaffee,et al.  A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction , 2011, Clinical Cancer Research.

[125]  J. Le Pecq,et al.  Increasing vaccine potency through exosome antigen targeting. , 2011, Vaccine.

[126]  R. Grossman,et al.  Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[127]  E. Rofstad,et al.  Magnetic resonance imaging of tumor necrosis , 2011, Acta oncologica.

[128]  Sabha Ganai,et al.  In tumors Salmonella migrate away from vasculature toward the transition zone and induce apoptosis , 2011, Cancer Gene Therapy.

[129]  N. Forbes.  Engineering the perfect (bacterial) cancer therapy , 2010, Nature Reviews Cancer.

[130]  H. Lyerly,et al.  Ligand-independent toll-like receptor signals generated by ectopic overexpression of MyD88 generate local and systemic antitumor immunity. , 2010, Cancer research.

[131]  W. Zimmermann,et al.  Efficient Eradication of Subcutaneous but Not of Autochthonous Gastric Tumors by Adoptive T Cell Transfer in an SV40 T Antigen Mouse Model , 2010, The Journal of Immunology.

[132]  L. Seymour,et al.  Blood compatibility of enveloped viruses. , 2010, Current opinion in molecular therapeutics.

[133]  Geng-sheng Zhang,et al.  The arrangement of subspaces in the orthogonal spaces and tighter analysis of an error-tolerant pooling design , 2010, J. Comb. Optim..

[134]  S. Bhide,et al.  Phase I/II Study of Oncolytic HSVGM-CSF in Combination with Radiotherapy and Cisplatin in Untreated Stage III/IV Squamous Cell Cancer of the Head and Neck , 2010, Clinical Cancer Research.

[135]  K. Santacruz,et al.  Anti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapy. , 2010, Vaccine.

[136]  Hyung-Seok Kim,et al.  Inhibition of tumor growth and metastasis by a combination of Escherichia coli-mediated cytolytic therapy and radiotherapy. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[137]  N. Tomiyama,et al.  Vascular supply with angio-CT for superselective intra-arterial chemotherapy in advanced maxillary sinus cancer. , 2010, The British journal of radiology.

[138]  F. Ginhoux,et al.  The origin and development of nonlymphoid tissue CD103+ DCs , 2009, The Journal of experimental medicine.

[139]  K. Harrington,et al.  Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[140]  N. Forbes,et al.  Tumour-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in mice , 2009, British Journal of Cancer.

[141]  W. Falk,et al.  Tumor Invasion of Salmonella enterica Serovar Typhimurium Is Accompanied by Strong Hemorrhage Promoted by TNF-α , 2009, PloS one.

[142]  S. H. Kim,et al.  High efficacy of a Listeria-based vaccine against metastatic breast cancer reveals a dual mode of action. , 2009, Cancer research.

[143]  R. Madan,et al.  Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer , 2009, Expert opinion on investigational drugs.

[144]  S. Radulović,et al.  The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. , 2009, Vaccine.

[145]  P. Maciag,et al.  An Anti-Vascular Endothelial Growth Factor Receptor 2/Fetal Liver Kinase-1 Listeria monocytogenes Anti-Angiogenesis Cancer Vaccine for the Treatment of Primary and Metastatic Her-2/neu+ Breast Tumors in a Mouse Model1 , 2009, The Journal of Immunology.

[146]  L. Pelner,et al.  Effects of concurrent infections and their toxins on the course of leukemia. , 2009, Acta medica Scandinavica. Supplementum.

[147]  P. Sinha,et al.  Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer 1 , 2009, The Journal of Immunology.

[148]  T. Mogensen.  Pathogen Recognition and Inflammatory Signaling in Innate Immune Defenses , 2009, Clinical Microbiology Reviews.

[149]  Jie Tian,et al.  Adenovirus Activates Complement by Distinctly Different Mechanisms In Vitro and In Vivo: Indirect Complement Activation by Virions In Vivo , 2009, Journal of Virology.

[150]  C. Lewis,et al.  Bacterial delivery of a novel cytolysin to hypoxic areas of solid tumors , 2009, Gene Therapy.

[151]  E. Unanue,et al.  Batf3 Deficiency Reveals a Critical Role for CD8α+ Dendritic Cells in Cytotoxic T Cell Immunity , 2008, Science.

[152]  John Calvin Reed,et al.  Inhibition of Tumor Growth Using Salmonella Expressing Fas Ligand , 2008, Journal of the National Cancer Institute.

[153]  Roberto Cattaneo,et al.  Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded , 2008, Nature Reviews Microbiology.

[154]  Steve Thorne,et al.  Directed Evolution Generates a Novel Oncolytic Virus for the Treatment of Colon Cancer , 2008, PloS one.

[155]  S. Porwollik,et al.  Salmonella promoters preferentially activated inside tumors. , 2008, Cancer research.

[156]  D. Saltzman,et al.  Attenuated Salmonella typhimurium with interleukin 2 gene prevents the establishment of pulmonary metastases in a model of osteosarcoma. , 2008, Journal of pediatric surgery.

[157]  C. Contag,et al.  Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery , 2008, Gene Therapy.

[158]  S. Weiss,et al.  Containment of tumor-colonizing bacteria by host neutrophils. , 2008, Cancer research.

[159]  W. Goebel,et al.  Prodrug converting enzyme gene delivery by L. monocytogenes , 2008, BMC Cancer.

[160]  Z. Guo,et al.  Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. , 2008, Biochimica et biophysica acta.

[161]  K. Ulbrich,et al.  Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[162]  S. Hassenbusch,et al.  Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. , 2008, Neuro-oncology.

[163]  C. Springer,et al.  Carboxypeptidase G2-based gene-directed enzyme–prodrug therapy: a new weapon in the GDEPT armoury , 2007, Nature Reviews Cancer.

[164]  David T. Curiel,et al.  Engineering targeted viral vectors for gene therapy , 2007, Nature Reviews Genetics.

[165]  Rachel W. Kasinskas,et al.  Salmonella typhimurium lacking ribose chemoreceptors localize in tumor quiescence and induce apoptosis. , 2007, Cancer research.

[166]  S. Russell,et al.  History of oncolytic viruses: genesis to genetic engineering. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[167]  S. Wells,et al.  The Role of Prophylactic Surgery in Cancer Prevention , 2007, World Journal of Surgery.

[168]  S. Thorne.  Strategies to achieve systemic delivery of therapeutic cells and microbes to tumors , 2007, Expert opinion on biological therapy.

[169]  N. Forbes.  Profile of a bacterial tumor killer , 2006, Nature Biotechnology.

[170]  Hiroyuki Aburatani,et al.  Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis , 2006, Nature Cell Biology.

[171]  R. Coombes,et al.  A Phase I Study of OncoVEXGM-CSF, a Second-Generation Oncolytic Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating Factor , 2006, Clinical Cancer Research.

[172]  D. Lowy,et al.  Prospects for cervical cancer prevention by human papillomavirus vaccination. , 2006, Cancer research.

[173]  P. Lambin,et al.  Development of a flexible and potent hypoxia-inducible promoter for tumor-targeted gene expression in attenuated salmonella , 2006, Cancer biology & therapy.

[174]  Rachel W. Kasinskas,et al.  Salmonella typhimurium specifically chemotax and proliferate in heterogeneous tumor tissue in vitro , 2006, Biotechnology and bioengineering.

[175]  Shuanglin Xiang,et al.  Short hairpin RNA–expressing bacteria elicit RNA interference in mammals , 2006, Nature Biotechnology.

[176]  B. Peters,et al.  Pharmacologic and toxicologic evaluation of C. novyi-NT spores. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.

[177]  M. Sznol,et al.  Systemic Administration of an Attenuated, Tumor-Targeting Salmonella typhimurium to Dogs with Spontaneous Neoplasia: Phase I Evaluation , 2005, Clinical Cancer Research.

[178]  Meng Yang,et al.  Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[179]  I. Frazer,et al.  Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. , 2004, Vaccine.

[180]  Bert Vogelstein,et al.  Bacteriolytic therapy can generate a potent immune response against experimental tumors. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[181]  R. Schreiber,et al.  The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.

[182]  J. Brown,et al.  Exploiting tumour hypoxia in cancer treatment , 2004, Nature Reviews Cancer.

[183]  G. Parmigiani,et al.  Targeting Vascular and Avascular Compartments of Tumors with C. novyi-NT and Anti-microtubule Agents , 2004, Cancer biology & therapy.

[184]  C. Bettegowda,et al.  Combination bacteriolytic cancer therapy: Attacking cancer from inside out. , 2004, Discovery medicine.

[185]  N. Minton.  Clostridia in cancer therapy , 2003, Nature Reviews Microbiology.

[186]  Bert Vogelstein,et al.  Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[187]  S. A. Cann,et al.  Dr William Coley and tumour regression: a place in history or in the future , 2003 .

[188]  I. H. Engels,et al.  Staphylococcus aureus α-toxin-induced cell death: predominant necrosis despite apoptotic caspase activation , 2003, Cell Death and Differentiation.

[189]  N. Senzer,et al.  Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients , 2003, Cancer Gene Therapy.

[190]  G. Viero,et al.  Ion channels and bacterial infection: the case of β‐barrel pore‐forming protein toxins of Staphylococcus aureus , 2003, FEBS letters.

[191]  Dai Fukumura,et al.  Sparse initial entrapment of systemically injected Salmonella typhimurium leads to heterogeneous accumulation within tumors. , 2003, Cancer research.

[192]  S. Rosenberg,et al.  Continuous intravenous administration of live genetically modified salmonella typhimurium in patients with metastatic melanoma. , 2003, Journal of immunotherapy.

[193]  K. Kinzler,et al.  Combination bacteriolytic therapy for the treatment of experimental tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[194]  J. Nemunaitis,et al.  A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001. , 2001, Human gene therapy.

[195]  P. Lambin,et al.  Radio-responsive recA promoter significantly increases TNFα production in recombinant clostridia after 2 Gy irradiation , 2001, Gene Therapy.

[196]  P. Lambin,et al.  Increasing specificity of anti-tumor therapy: cytotoxic protein delivery by non-pathogenic clostridia under regulation of radio-induced promoters. , 2001, Anticancer research.

[197]  K. Ulbrich,et al.  Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies , 2001, Gene Therapy.

[198]  X. Luo,et al.  Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium. , 2000, The Journal of infectious diseases.

[199]  M. Sznol,et al.  Use of preferentially replicating bacteria for the treatment of cancer. , 2000, The Journal of clinical investigation.

[200]  J. Schlom,et al.  A triad of costimulatory molecules synergize to amplify T-cell activation. , 1999, Cancer research.

[201]  P. Lambin,et al.  Stable Escherichia coli-Clostridium acetobutylicum Shuttle Vector for Secretion of Murine Tumor Necrosis Factor Alpha , 1999, Applied and Environmental Microbiology.

[202]  M. Richardson,et al.  Coley toxins immunotherapy: a retrospective review. , 1999, Alternative therapies in health and medicine.

[203]  D. Shapiro,et al.  The construct of control in mind-body medicine: implications for healthcare. , 1999, Alternative therapies in health and medicine.

[204]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[205]  P. Lambin,et al.  Colonisation of Clostridium in the body is restricted to hypoxic and necrotic areas of tumours. , 1998, Anaerobe.

[206]  E. Gilboa,et al.  Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA , 1998, Nature Biotechnology.

[207]  J. Pawelek,et al.  Tumor-targeted Salmonella as a novel anticancer vector. , 1997, Cancer research.

[208]  J. Gouaux,et al.  Structure of Staphylococcal α-Hemolysin, a Heptameric Transmembrane Pore , 1996, Science.

[209]  B. Birren,et al.  Cloning and stable maintenance of 300-kilobase-pair fragments of human DNA in Escherichia coli using an F-factor-based vector. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[210]  D M Coen,et al.  Experimental therapy of human glioma by means of a genetically engineered virus mutant , 1991, Science.

[211]  D. Portnoy,et al.  Actin filaments and the growth, movement, and spread of the intracellular bacterial parasite, Listeria monocytogenes , 1989, The Journal of cell biology.

[212]  J L Middlebrook,et al.  Bacterial toxins: cellular mechanisms of action , 1984, Microbiological reviews.

[213]  M. Hilleman,et al.  Purified and inactivated human hepatitis B vaccine: progress report. , 1975, The American journal of the medical sciences.

[214]  E. Neter,et al.  Clostridial oncolysis in man , 1967 .

[215]  J. Moese,et al.  ONCOLYSIS BY CLOSTRIDIA. I. ACTIVITY OF CLOSTRIDIUM BUTYRICUM (M-55) AND OTHER NONPATHOGENIC CLOSTRIDIA AGAINST THE EHRLICH CARCINOMA. , 1964, Cancer research.

[216]  M. F. D'Herelle.  Sur un microbe invisible antagoniste des bacilles dysenteriques , 1961 .

[217]  E. von Haam,et al.  Studies in Hodgkin's syndrome; the association of viral hepatitis and Hodgkin's disease; a preliminary report. , 1949, Cancer research.

[218]  C. A. Doan,et al.  Studies in Hodgkin's syndrome; nitrogen mustard therapy. , 1948, The Journal of laboratory and clinical medicine.

[219]  G. Dock.  The Influence Of Complicating Diseases Upon LeukÆmia. , 1904 .

[220]  M. Coffey,et al.  Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[221]  S. Dow,et al.  Cancer immunotherapy in veterinary medicine: Current options and new developments. , 2016, Veterinary journal.

[222]  Bacterial Therapy of Cancer. Methods and Protocols. , 2016, Anticancer research.

[223]  Joanna S Morris,et al.  Cancer immunology and canine malignant melanoma: A comparative review. , 2016, Veterinary immunology and immunopathology.

[224]  K. Kinzler,et al.  Evaluation of Clostridium novyi-NT spores in dogs with naturally occurring tumors. , 2012, American journal of veterinary research.

[225]  P. Maciag,et al.  Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human , 2011, Cancer Gene Therapy.

[226]  Karlyne M. Reilly,et al.  Genetically engineered mouse models in cancer research. , 2010, Advances in cancer research.

[227]  Hyung-Seok Kim,et al.  Genetically engineered Salmonella typhimurium as an imageable therapeutic probe for cancer. , 2010, Cancer research.

[228]  E. McCarthy.  The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. , 2006, The Iowa orthopaedic journal.

[229]  John Mao,et al.  Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[230]  E. Gouaux.  alpha-Hemolysin from Staphylococcus aureus: an archetype of beta-barrel, channel-forming toxins. , 1998, Journal of structural biology.

[231]  E. Gouaux.  α-Hemolysin fromStaphylococcus aureus:An Archetype of β-Barrel, Channel-Forming Toxins , 1998 .